Leo Pharma files at FDA a BLA for tralokinumab to treat moderate-to-severe atopic dermatitis.
LEO Pharma A/S, a global leader in medical dermatology, announced that the Biologics License Application (BLA) for tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD)… read more.